RxDoctor Payments Data

Terry Peery, DO

Neurology · Round Rock, TXNPI 1710959762

Payments from drug & device makers

$310,290in general payments, 2019–2025

Across 813 payments — averaging $381.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$120K
  • Harmony Biosciences LLC$115K
  • Jazz Pharmaceuticals Inc.$48K
  • GW Research Limited$13K
  • UCB, Inc.$2K
  • Inspire Medical Systems, Inc.$1K
  • plus $12K from 54 others

What the payments were for

  • Speaking & faculty fees$881%
  • Travel & lodging$1,3889%
  • Food & beverage$14,07389%
  • Education$2442%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB SA18$119,770
Harmony Biosciences LLC72$114,654
Jazz Pharmaceuticals Inc.53$47,815
GW Research Limited5$13,169
UCB, Inc.77$1,792
Inspire Medical Systems, Inc.14$1,467
Medtronic8$962
Novartis45$740
Sanofi31$706
Genentech USA, Inc.45$665
Lilly USA, LLC41$645
Amgen28$612
SK Life Science, Inc.26$551
Teva Pharmaceuticals USA, Inc.29$496
AbbVie(2 entities)27$474
Neurocrine Biosciences, Inc.23$410
Pfizer38$399
Livanova USA, Inc.3$354
Biogen16$353
AstraZeneca15$350
Upsher-smith Laboratories LLC16$334
Argenx US, Inc.11$290
Acadia Pharmaceuticals Inc17$258
Sunovion Pharmaceuticals Inc.18$249
Lundbeck LLC11$242
Alnylam Pharmaceuticals Inc.6$199
Biohaven Pharmaceutical Holding Company Ltd.14$194
Greenwich Biosciences, Inc.7$186
Acorda Therapeutics, Inc7$141
Biohaven Pharmaceuticals, Inc.9$133
Avanir Pharmaceuticals, Inc.10$130
Eisai Inc.6$122
Octapharma USA, Inc.3$117
EMD Serono, Inc.6$111
Tanabe Pharma America, Inc.6$111
Amylyx Pharmaceuticals, Inc.4$107
Avadel CNS Pharmaceuticals, LLC6$105
Currax Pharmaceuticals LLC5$80
Neuropace, Inc.1$72
Catalyst Pharmaceuticals, Inc.3$66
Merz Pharmaceuticals, LLC2$64
Grifols USA, LLC3$60
Amicus Therapeutics, Inc.3$59
Averitas Pharma Inc.2$50
Arbor Pharmaceuticals, Inc.4$45
ANI Pharmaceuticals, Inc.1$44
Neurelis, Inc.2$38
Abbott2$37
Corium, LLC1$32
Sanofi-aventis U.S. LLC1$24
Merz North America, Inc.1$24
Sumitomo Pharma America, Inc.1$24
Axsome Therapeutics, Inc.1$20
Otsuka America Pharmaceutical, Inc.1$19
Idorsia Pharmaceuticals US Inc1$18
Life Molecular Imaging Ltd1$17
Johnson & Johnson1$17
Azurity Pharmaceuticals, Inc.1$15
MDD US Operations, LLC1$15
Promius Pharma LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$310,290 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$133,192
Medicare patients
395
Services billed
970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sodium Oxybate14$251,315
AfinitorEverolimus13$241,720
EpidiolexCannabidiol (Cbd)45$140,860
BriviactBrivaracetam27$81,659
OnfiClobazam13$49,840
Lacosamide92$30,671
SunosiSolriamfetol Hcl16$13,924
Levetiracetam308$10,520
Levetiracetam ErLevetiracetam47$7,653
Doxepin Hcl19$6,379
Lisdexamfetamine Dimesylate13$3,528
Carbamazepine ErCarbamazepine21$3,219
Zonisamide60$2,832
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine22$2,425
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen44$2,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisAfinitor$740$241,72013 claims
UCB, Inc.Briviact$1,792$81,65927 claims
Lundbeck LLCOnfi$242$49,84013 claims
Axsome Therapeutics, Inc.Sunosi$20$13,92416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.

Other neurology in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →